Tags

Type your tag names separated by a space and hit enter

Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Semin Thromb Hemost 2009; 35(3):313-24ST

Abstract

Psoriasis is a chronic inflammatory, immune-mediated skin disease affecting 2 to 3% of the general population and may cause significant quality-of-life impairment. Psoriasis and psoriatic arthritis are associated with increased atherothrombotic diseases, including myocardial infarction, deep venous thrombosis, and reduced life span. Both disease-specific and non-disease-specific risk factors are likely to fuel one another in deleterious vicious circles. Disease-specific risk factors are those that are a direct consequence of psoriasis inflammation and include hyperhomocysteinemia, elevated C-reactive protein, elevated blood inflammatory cytokines, and platelet hyperactivity. Non-disease-specific risk factors include insulin resistance/diabetes, obesity, dyslipidemia, hypertension, metabolic syndrome, and habitual tobacco smoking. The presence of cardio-metabolic comorbidities has also relevant implication in the therapy and global approach to patients with psoriasis. Traditional systemic antipsoriatic agents frequently negatively affect cardio-metabolic comorbidities and may have important interactions with drugs commonly used by psoriasis patients. Thus, patients with psoriasis should be treated effectively and encouraged to aggressively correct their modifiable cardiovascular risk factors.

Authors+Show Affiliations

Department of Biomedical and Surgical Science, University of Verona, Italy. paolo.gisondi@univr.itNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19452407

Citation

Gisondi, Paolo, and Giampiero Girolomoni. "Psoriasis and Atherothrombotic Diseases: Disease-specific and Non-disease-specific Risk Factors." Seminars in Thrombosis and Hemostasis, vol. 35, no. 3, 2009, pp. 313-24.
Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost. 2009;35(3):313-24.
Gisondi, P., & Girolomoni, G. (2009). Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Seminars in Thrombosis and Hemostasis, 35(3), pp. 313-24. doi:10.1055/s-0029-1222610.
Gisondi P, Girolomoni G. Psoriasis and Atherothrombotic Diseases: Disease-specific and Non-disease-specific Risk Factors. Semin Thromb Hemost. 2009;35(3):313-24. PubMed PMID: 19452407.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. AU - Gisondi,Paolo, AU - Girolomoni,Giampiero, Y1 - 2009/05/18/ PY - 2009/5/20/entrez PY - 2009/5/20/pubmed PY - 2009/6/27/medline SP - 313 EP - 24 JF - Seminars in thrombosis and hemostasis JO - Semin. Thromb. Hemost. VL - 35 IS - 3 N2 - Psoriasis is a chronic inflammatory, immune-mediated skin disease affecting 2 to 3% of the general population and may cause significant quality-of-life impairment. Psoriasis and psoriatic arthritis are associated with increased atherothrombotic diseases, including myocardial infarction, deep venous thrombosis, and reduced life span. Both disease-specific and non-disease-specific risk factors are likely to fuel one another in deleterious vicious circles. Disease-specific risk factors are those that are a direct consequence of psoriasis inflammation and include hyperhomocysteinemia, elevated C-reactive protein, elevated blood inflammatory cytokines, and platelet hyperactivity. Non-disease-specific risk factors include insulin resistance/diabetes, obesity, dyslipidemia, hypertension, metabolic syndrome, and habitual tobacco smoking. The presence of cardio-metabolic comorbidities has also relevant implication in the therapy and global approach to patients with psoriasis. Traditional systemic antipsoriatic agents frequently negatively affect cardio-metabolic comorbidities and may have important interactions with drugs commonly used by psoriasis patients. Thus, patients with psoriasis should be treated effectively and encouraged to aggressively correct their modifiable cardiovascular risk factors. SN - 1098-9064 UR - https://www.unboundmedicine.com/medline/citation/19452407/Psoriasis_and_atherothrombotic_diseases:_disease_specific_and_non_disease_specific_risk_factors_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1222610 DB - PRIME DP - Unbound Medicine ER -